Sermorelin in Laboratory Research: A Structured Review of Preclinical and Clinical Studies

Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It acts as a GHRH receptor agonist, stimulating pituitary somatotroph cells to secrete growth hormone (GH). Since its development, sermorelin has been employed as a research tool to probe the somatotropic axis and has been evaluated in various preclinical and clinical studies. This review outlines the scope of those studies, their principal findings, and considerations for interpretation.

Preclinical Studies

In rodent models, sermorelin administration has been shown to increase plasma GH levels in a dose-dependent manner. Studies in rats and mice have demonstrated that subcutaneous or intravenous bolus injections of sermorelin elicit rapid, pulsatile GH release, mimicking endogenous GHRH action. Repeated dosing studies in aged rodents have reported partial restoration of GH pulsatility and increases in insulin-like growth factor 1 (IGF-1) levels, suggesting potential utility in models of age-related GH decline. However, species differences in GHRH receptor affinity and pharmacokinetics limit direct extrapolation to humans.

In vitro studies using primary pituitary cell cultures have confirmed that sermorelin binds to GHRH receptors and activates adenylate cyclase, leading to increased intracellular cAMP and GH secretion. These experiments have been valuable for dissecting signal transduction pathways and for comparing sermorelin's potency with that of native GHRH and other analogs.

Clinical Studies

Early clinical investigations in healthy adults and in individuals with GH deficiency established that sermorelin stimulates GH release in a dose-dependent fashion. Single-dose studies typically measured GH peaks within 15–30 minutes after intravenous administration, with a return to baseline within 2–3 hours. In children with idiopathic GH deficiency, short-term sermorelin treatment increased growth velocity in some trials, but responses varied, and long-term efficacy data are limited.

In older adults, several small randomized controlled trials examined the effects of sermorelin on body composition, muscle strength, and IGF-1 levels. Some studies reported modest increases in lean body mass and IGF-1, but others found no significant differences compared with placebo. Variability in dosing regimens, treatment duration, and outcome measures complicates cross-study comparisons. Additionally, the pulsatile nature of GH secretion and the influence of negative feedback loops make it difficult to attribute observed changes solely to sermorelin.

Diagnostic studies have used sermorelin as a provocative agent to assess pituitary GH reserve. In this context, sermorelin stimulation tests have been compared with other secretagogues (e.g., insulin-induced hypoglycemia, arginine, clonidine). While sermorelin is generally well tolerated, its diagnostic sensitivity and specificity relative to standard tests remain an area of investigation.

Safety and Pharmacokinetics

Across clinical studies, sermorelin has been reported to be generally well tolerated, with transient injection-site reactions being the most common adverse event. Systemic effects such as flushing, headache, and dizziness have been noted but are typically mild and self-limiting. Pharmacokinetic studies indicate a short plasma half-life (approximately 10–20 minutes), necessitating frequent administration or sustained-release formulations in chronic studies. Antibody formation against sermorelin has been observed in some long-term trials, which may attenuate its efficacy.